These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15565804)

  • 41. Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis.
    Li Z; Bian LJ; Li Y; Liang YJ; Liang HZ
    Pathol Res Pract; 2009; 205(8):542-50. PubMed ID: 19269113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma.
    Pathmanathan R; Prasad U; Sadler R; Flynn K; Raab-Traub N
    N Engl J Med; 1995 Sep; 333(11):693-8. PubMed ID: 7637746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salivary gland type nasopharyngeal carcinoma: a histologic, immunohistochemical, and Epstein-Barr virus study of 15 cases including a psammomatous mucoepidermoid carcinoma.
    Kuo T; Tsang NM
    Am J Surg Pathol; 2001 Jan; 25(1):80-6. PubMed ID: 11145255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epstein Barr virus associated pediatric nasopharyngeal carcinoma: its correlation with p53 and bcl-2 expression.
    Preciado MV; Chabay PA; De Matteo EN; Gismondi MI; Rey G; Zubizarreta P
    Med Pediatr Oncol; 2002 May; 38(5):345-8. PubMed ID: 11979459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of LMP-1 gene in middle ear effusion of NPC.
    Hao SP; Tsang NM; Chen YL; Chang KP; Su JL
    Oral Oncol; 2003 Apr; 39(3):296-300. PubMed ID: 12618203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
    Li SW; Wang H; Xiang YQ; Zhang HB; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Head Neck; 2013 Apr; 35(4):579-91. PubMed ID: 22605662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-associated nasopharyngeal carcinoma cells.
    Ma L; Deng X; Wu M; Zhang G; Huang J
    FEBS Lett; 2014 May; 588(9):1562-70. PubMed ID: 24613926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The time frame of Epstein-Barr virus latent membrane protein-1 gene to disappear in nasopharyngeal swabs after initiation of primary radiotherapy is an independently significant prognostic factor predicting local control for patients with nasopharyngeal carcinoma.
    Lin SY; Chang KP; Hsieh MS; Ueng SH; Hao SP; Tseng CK; Pai PC; Chang FT; Tsai MH; Tsang NM
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1339-46. PubMed ID: 16169672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs.
    Hao SP; Tsang NM; Chang KP
    Cancer; 2003 Apr; 97(8):1909-13. PubMed ID: 12673717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of LMP-1 expression on neoplastic cell proliferation and apoptosis in nasopharyngeal carcinoma].
    Li Z; Zong Y
    Zhonghua Bing Li Xue Za Zhi; 1999 Oct; 28(5):340-3. PubMed ID: 11869545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response.
    Gondhowiardjo S
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():323-31. PubMed ID: 10895175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma.
    Sheen TS; Huang YT; Chang YL; Ko JY; Wu CS; Yu YC; Tsai CH; Hsu MM
    Jpn J Cancer Res; 1999 Dec; 90(12):1285-92. PubMed ID: 10665644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
    Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
    Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
    Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
    Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Ogino T; Moriai S; Ishida Y; Ishii H; Katayama A; Miyokawa N; Harabuchi Y; Ferrone S
    Int J Cancer; 2007 Jun; 120(11):2401-10. PubMed ID: 17315195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
    Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.